Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
Avatar

2020 Updates on MDS: Is Deferasirox Beneficial for EFS? Can We Achieve Transfusion Independence With Luspatercept? Does IV-DEC Mono Prolong the Duration of Response?

By 7th Eurasian Hematology Oncology Summit FEATURING Guillermo Garcia-Manero
By 7th Eurasian Hematology Oncology Summit FEATURING Guillermo Garcia-Manero
168 views
December 11, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip
MDS and MPN
15:05

2020 Updates on MDS: Is Deferasirox Beneficial for EFS? Can We Achie…

7th Eurasian Hematology Oncology Summit

G. Garcia-Manero

168 views
18:36

2020 Update on High-Risk MDS: Does Aza Improve OS/ORR? How to Minimi…

7th Eurasian Hematology Oncology Summit

M. Mittelman

64 views
11:32

2020 Updates on MDS: Role of Prognostic Models, Cytogenetics, IPSS, …

7th Eurasian Hematology Oncology Summit

G. Garcia-Manero

96 views
26:20

2020 Update on MPNs: What Is the Risk Adapted Management in PV? Is R…

7th Eurasian Hematology Oncology Summit

T. Mughal

117 views